Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,368 shares of the biopharmaceutical company’s stock after selling 20,677 shares during the quarter. Goldman Sachs Group Inc. owned 0.23% of Alnylam Pharmaceuticals worth $55,771,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quent Capital LLC increased its holdings in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $38,000. Robeco Institutional Asset Management B.V. increased its stake in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Finally, V Square Quantitative Management LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $52,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 2.2 %

ALNY stock opened at $153.86 on Wednesday. The company has a market cap of $19.46 billion, a PE ratio of -57.41 and a beta of 0.30. The stock has a 50-day moving average price of $150.01 and a two-hundred day moving average price of $162.56. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.40) earnings per share. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALNY. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. HC Wainwright raised their price target on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Finally, Chardan Capital restated a “buy” rating and set a $225.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $216.19.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.